sequence under fasting condition and at least 7 days washout period between the doses.

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Pregabalin Capsules 75 mg of Cadila Healthcare Ltd., India relative to LYRICATM (Pregabalin) Capsules 75 mg of Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levetiracetam Tablets USP 500 mg of Cadila Healthcare Ltd., India relative to Keppra® 500 mg (Levetiracetam Tablets USP 500 mg) of UCB Pharma SA Braine-LʽAlleud, Belgium in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin Tablets USP 100 mg of Cadila Healthcare Ltd., India relative to JanuviaTM 100 mg (Sitagliptin Tablets 100 mg) of MERCK SHARP & DOHME Ltd, The United Kingdom in healthy Thai volunteers under fasting condition